Daniel Lorrain
Patrimonio netto: 2 M $ in data 31/07/2026
Patrimonio netto: 2 M $ in data 31/07/2026
Daniel S.
Lorrain is the founder of Contineum Therapeutics, Inc., founded in 2017, serving as Chief Scientific Officer since 2018.
Former jobs include Senior Director at Amira Pharmaceuticals, Inc. from 2005 to 2010, and Vice President-Biology at Inception Sciences, Inc. from 2016 to 2018.
Education includes an undergraduate degree conferred in 1991 and a doctorate conferred in 1997, both from the State University of New York at Buffalo.
| Società | Data | Numero di azioni | Valutazione | Data di valutazione |
|---|---|---|---|---|
| 09/07/2026 | 145.312 ( 0,44% ) | 2 M $ | 31/07/2026 |
| Società | Posizione | Inizio |
|---|---|---|
| CONTINEUM THERAPEUTICS, INC. | Fondatore | 09/05/2017 |
| Società | Posizione | Fine |
|---|---|---|
Inception Sciences, Inc.
Inception Sciences, Inc. Pharmaceuticals: MajorHealth Technology Provides small molecule pharmaceutical incubator services | Direttore/Membro del Consiglio | 10/01/2018 |
Amira Pharmaceuticals, Inc.
Amira Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Manufactures biopharmaceutical products | Direttore/Membro del Consiglio | 01/11/2010 |
Attive
Inattive
Società nel listino
Aziende private
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
| Aziende private | 4 |
|---|---|
Amira Pharmaceuticals, Inc.
Amira Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Manufactures biopharmaceutical products | Health Technology |
State University of New York at Buffalo
State University of New York at Buffalo Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Inception Sciences, Inc.
Inception Sciences, Inc. Pharmaceuticals: MajorHealth Technology Provides small molecule pharmaceutical incubator services | Health Technology |
Pipeline Therapeutics, Inc.
Pipeline Therapeutics, Inc. BiotechnologyHealth Technology Operates as a clinical stage biopharmaceutical company that develops novel, oral small molecule therapies for neuroscience, inflammation and immunology indications | Health Technology |
Seleziona la tua edizione
Tutte le informazioni finanziarie adattate in base al livello nazionale